Emergent BioSolutions Gets Anthrax Vaccine Contract Modification up to $22.3m

Dow Jones06:44

Emergent BioSolutions received a contract modification valued at up to $22.3 million to supply its BioThrax vaccine to the Defense Department.

The company said the modification, which exercises an option period under its existing contract with the Pentagon, includes an initial delivery valued around $7.4 million set to take place this year. Remaining deliveries are expected to occur next year.

"We're pleased to continue supporting the Department of War's efforts to maintain preparedness against critical biological threats like anthrax," the company's head of products business, global government and public affairs, Paul Williams, said Wednesday. "Delivering dependable access to BioThrax helps protect our nation's service members who have an elevated risk of anthrax exposure."

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment